Ambit Biosciences

Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases.[1]:3[n 1] As of March 2014, the company was based in San Diego, California and consisted of a single facility.[2]:58 Ambit made an initial public offering in May 2013[2] and was listed on the NASDAQ exchange under the symbol "AMBI".[3] Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange.

Products

As of March 2014, three products were under development, of which quizartinib was their lead drug candidate.[1]:3

Business model

As of March 2014, Ambit sought to develop new therapeutics through internal, proprietary research, which is evidenced by their pipeline of three products consisting entirely of internally developed therapeutics.[1]:3 Further, Ambit aimed to be a full life cycle pharmaceutical company by conducting discovery, development and further commercialization of therapeutics.[1]:3

Among the firms who invested heavily in Ambit prior to its initial public offering was Foresite Capital in January 2013.[3]

In November of 2014, Ambit was acquired by Daiichi Sankyo.[4]

References

  1. 1 2 3 4 "Form 10-K: Ambit Biosciences Corporation. Commission file number: 001-35919". EDGAR. U.S. Securities and Exchange Commission. March 20, 2014. Retrieved 2017-06-27.
  2. 1 2 Huggett, Brady (December 2013). "Burning bright". Nature Biotechnology. 31 (12): 1068–1071. doi:10.1038/nbt.2766.
  3. 1 2 Fidler, Ben (2014-04-01). "Foresite Capital Reloads With New $300M Late-Stage Biotech Fund". Xconomy. Retrieved 2017-06-27.
  4. ↑ Fikes, Bradley J. (2017-01-16). "Local biotech turning to Japan for partnerships". The San Diego Union-Tribune. Retrieved 2017-06-27.

Notes

  1. ↑ The SEC 10K submission for 2013 indicates that the company is a "biopharmaceutical" company, which implies that they are primarily developing biopharmaceuticals; however their lead product is a small molecule therapeutic, calling into question the term used in the SEC submission.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.